References
Mazharuddin S, Chattopadhyay A, Levy MY, Redner RL (2018) IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid. Leuk Lymphoma 59(9):2246–2249. https://doi.org/10.1080/10428194.2017.1421761
Soliman H, Khalil F, Antonia S (2014) PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS ONE 9(2):e88557. https://doi.org/10.1371/journal.pone.0088557
Blotta S, Tassone P, Prabhala RH et al (2009) Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 114(15):3276–3284. https://doi.org/10.1182/blood-2009-04-219436
Nyquist KB, Panagopoulos I, Thorsen J et al (2012) Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma. PLoS ONE 7(11):e49705. https://doi.org/10.1371/journal.pone.0049705
Alotaibi AS, Abdulrazzaq M, Patel KP, Ravandi F, Konoplev S, Bueso-Ramos C, Yin CC, Muzzafar T, Tang G, Futreal A, Jain N, Konopleva MY, Pemmaraju N (2020) Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leuk Lymphoma 61(12):3018–3020
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Yang, X., Zhang, R. & Zhang, Z. The rare IRF2BP2-RARA fusion in acute promyelocytic leukemia. Ann Hematol 101, 2101–2102 (2022). https://doi.org/10.1007/s00277-022-04874-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-022-04874-z